Search

Your search keyword '"Defer, Gilles"' showing total 535 results

Search Constraints

Start Over You searched for: Author "Defer, Gilles" Remove constraint Author: "Defer, Gilles"
535 results on '"Defer, Gilles"'

Search Results

4. Real-World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

6. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis

9. Résultats de l’étude d’extension NOVA évaluant la préférence des patients pour l’administration sous-cutanée (SC) versus intraveineuse (IV) de natalizumab (NTZ) avec le schéma Q6W (toutes les 6 semaines)

10. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

11. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing–Remitting Multiple Sclerosis After Fingolimod Withdrawal

12. Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference

13. Acute Clinical Events Identified as Relapses With Stable Magnetic Resonance Imaging in Multiple Sclerosis.

14. Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society

16. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.

18. Comparison of 2 Methods for Estimating Multiple Sclerosis–Related Mortality

21. Descriptive analysis of the French NS-Park registry: Towards a nation-wide Parkinson's disease cohort?

22. Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.

23. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

24. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

28. Historique de la sclérose en plaques

29. Immunologie de la sclérose en plaques

30. Épidémiologie, environnement et génétique dans la sclérose en plaques

31. Histoire naturelle de la sclérose en plaques

34. Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: a retrospective observational cohort study

36. The radiologically isolated syndrome: revised diagnostic criteria

37. Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study

38. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis

39. The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus

40. Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system

42. Transverse Myelitis Following SARS‐CoV‐2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database

44. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

49. Primary Results of NOVA: a Randomized Controlled Study of the Efficacy of 6 - Week Dosing of Natalizumab Versus Continued 4-Week Treatment for Multiple Sclerosis (S14.005)

50. Résultats primaires de NOVA : une étude contrôlée randomisée comparant l’administration de natalizumab toutes les 6 semaines versus une administration continue toutes les 4 semaines dans le traitement de la sclérose en plaques

Catalog

Books, media, physical & digital resources